Citation: B. Jarvis et A. Markham, Inhaled salmeterol - A review of its efficacy in chronic obstructive pulmonary disease, DRUG AGING, 18(6), 2001, pp. 441-472
Citation: A. Markham et Jc. Adkins, Inhaled salmeterol/fluticasone propionate combination - A pharmacoeconomicreview of its use in the management of asthma, PHARMACOECO, 18(6), 2000, pp. 591-608
Authors:
Spedding, M
Menton, K
Markham, A
Weetman, DF
Citation: M. Spedding et al., Antagonists and the purinergic nerve hypothesis: 2,2 '-pyridylisatogen tosylate (PIT), an allosteric modulator of P2Y receptors. A retrospective on aquarter century of progress, J AUTON NER, 81(1-3), 2000, pp. 225-227
Citation: A. Markham et B. Jarvis, Inhaled salmeterol/fluticasone propionate combination - A review of its use in persistent asthma, DRUGS, 60(5), 2000, pp. 1207-1233
Citation: A. Markham et al., Nicorandil - An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects, DRUGS, 60(4), 2000, pp. 955-974
Citation: D. Clemett et A. Markham, Prolonged-release mesalazine - A review of its therapeutic potential in ulcerative colitis and Crohn's disease, DRUGS, 59(4), 2000, pp. 929-956
Citation: M. Haria et al., Felodipine/Metoprolol - A review of the fixed dose controlled release formulation in the management of essential hypertension, DRUGS, 59(1), 2000, pp. 141-157
Authors:
Toomes, C
James, J
Wood, AJ
Wu, CL
McCormick, D
Lench, N
Hewitt, C
Moynihan, L
Roberts, E
Woods, CG
Markham, A
Wong, M
Widmer, R
Ghaffar, KA
Pemberton, M
Hussein, IR
Temtamy, SA
Davies, R
Read, AP
Sloan, P
Dixon, MJ
Thakker, NS
Citation: C. Toomes et al., Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis, NAT GENET, 23(4), 1999, pp. 421-424
Citation: Kl. Simpson et A. Markham, Ofloxacin otic solution - A review of its use in the management of ear infections, DRUGS, 58(3), 1999, pp. 509-531